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Abstract
Resistance to complement mediated killing, or serum resistance, is a common trait of pathogenic bacteria. Rck is a 17 kDa
outer membrane protein encoded on the virulence plasmid of Salmonella enterica serovars Typhimurium and Enteritidis.
When expressed in either E. coli or S. enterica Typhimurium, Rck confers LPS-independent serum resistance as well as the
ability to bind to and invade mammalian cells. Having recently shown that Rck binds the inhibitor of the alternative
pathway of complement, factor H (fH), we hypothesized that Rck can also bind the inhibitor of the classical and lectin
pathways, C4b-binding protein (C4BP). Using flow cytometry and direct binding assays, we demonstrate that E. coli
expressing Rck binds C4BP from heat-inactivated serum and by using the purified protein. No binding was detected in the
absence of Rck expression. C4BP bound to Rck is functional, as we observed factor I-mediated cleavage of C4b in cofactor
assays. In competition assays, binding of radiolabeled C4BP to Rck was reduced by increasing concentrations of unlabeled
protein. No effect was observed by increasing heparin or salt concentrations, suggesting mainly non-ionic interactions.
Reduced binding of C4BP mutants lacking complement control protein domains (CCPs) 7 or 8 was observed compared to
wt C4BP, suggesting that these CCPs are involved in Rck binding. While these findings are restricted to Rck expression in E.
coli, these data suggest that C4BP binding may be an additional mechanism of Rck-mediated complement resistance.
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Introduction
Any successful human pathogen must possess mechanisms for
resisting complement, a key first-line defense of the innate immune
system. The complement system consists of approximately 40
proteins found in the fluid phase and on cell surfaces. Upon
recognition of an invader, this system is immediately activated via
one or several routes: the classical, lectin, or alternative pathways,
which all converge at the C3 step. Successful activation on a
pathogen surface leads to opsonization with C3b and its cleavage
product iC3b. Complement activation also results in generation of
inflammation via the released anaphylatoxins, and in the case of
gram-negative bacteria, direct lysis by the membrane attack
complex (MAC) [1]. Accordingly, pathogenic bacteria have
evolved effective mechanisms for evading or resisting complement
attack [2].
Serum resistance, or resistance to complement-mediated killing,
is a recognized virulence trait of Salmonella. Several diverse
mechanisms of serum resistance have been described, including
prevention of functional MAC insertion into the outer membrane
due to long-chain LPS [3,4], cleavage of complement components
C3, C4 and C5 by PgtE [5], and C6 inhibition by TraT [6]. The
outer membrane protein Rck has been shown to mediate serum
resistance by interfering with MAC function [7], while the
mechanism of serum resistance by the related protein, PagC, is
currently unknown [8].
Within the Enterobacteriaceae, a family of highly conserved 17–
19 kDa outer membrane proteins including Rck, PagC, OmpX
(E. coli and Enterobacter cloacae), and Ail (Yersinia) [9] has been
described. All these proteins have been shown to possess virulence
associated phenotypes. Based on structural models and the solved
crystal structure of OmpX [10], these proteins are predicted to
exhibit a common topology consisting of eight transmembrane
amphipathic b-strands and four surface exposed loops. The
regions of greatest homology are the transmembrane domains,
while the greatest sequence diversity is found in the surface
exposed loops, which presumably mediate interactions with the
host. This observation suggests that these proteins are functionally
dissimilar. Despite the fact that Rck, Ail, and PagC have been
shown to mediate serum resistance, it is not currently clear if these
proteins do so by conserved mechanisms.
Although the complement system plays a critical role in host
defense against infection, inappropriate or excessive activation can
lead to damage of self tissues. To ensure that complement
activation is restricted to the appropriate targets, the host has
evolved multiple cell surface and fluid phase inhibitors which
regulate complement at the steps of activation, amplification, and
membrane attack [11]. Not surprisingly, numerous pathogenic
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microbes have evolved the ability to recruit and exploit fluid-phase
complement inhibitors as a means of defense against complement
attack [2]. Particularly attractive targets for pathogens include
factor H (fH) and C4b-binding protein (C4BP), which are fluid-
phase inhibitors of the alternative (AP) and the classical (CP) and
the lectin pathway (LP), respectively. Functional recruitment of
one or both of these proteins would confer the ability to inhibit
complement activation at the convertase step, thus preventing
complement-mediated opsonization, inflammation, and lysis via
MAC.
C4BP is a key fluid phase inhibitor of the CP and LP. It is a
large glycoprotein with a plasma concentration of approximately
200 mg/ml. The major isoform found in plasma consists of 7
identical a chains and a single b chain. The a and b chains consist
of 8 and 3 complement control protein domains (CCPs),
respectively. C4BP regulates CP and LP mediated complement
activation by three mechanisms: by acting as a cofactor for factor I
(fI)-mediated cleavage and inactivation of C4b, by accelerating the
decay of the C4b2a convertase, and by preventing the assembly of
the convertase by binding to C4b [12]. Recruitment of C4BP as a
means of defense against complement attack has been demon-
strated in several bacterial pathogens such as N. gonorrhoeae [13], E.
coli K1 [14], S. pneumoniae [15], B. burgdorferi sensu lato [16] and H.
influenzae [17].
The Rck homologue in Y. enterocolitica, Ail, has been shown to
functionally recruit both fH [18] and C4BP [19]. Based on these
observations, we hypothesized that Rck possesses a similar ability.
We have recently shown that Rck binds and recruits fH in a
functional manner, and can protect serum-sensitive E. coli from
AP-mediated killing [20]. We have extended these observations
and demonstrate here that Rck can additionally bind the CP and
LP inhibitor C4BP. This binding is functional and specific, and
appears to involve CCPs 7 and 8 of C4BP. These results suggest
that Rck has the ability to functionally recruit multiple
complement inhibitors, thus conferring the ability to resist attack
from this key arm of innate immunity.
Materials and Methods
Ethics statement
All persons who donated blood for this study provided a written
informed consent. The study protocol has been approved by the
Section for Research of the Helsinki University Central Hospital
Laboratory (project TYH7214).
Bacterial plasmids, strains and growth
Serum-sensitive E. coli strain BL21(DE3) (Invitrogen, Carlsbad,
CA) was used for all experiments. Bacteria were grown in Luria-
Bertani (LB) broth cultures with shaking or on solid LB media at
37uC in room air. Plasmid pRck was used to express Rck
(GenBank: M76130.1) in E. coli BL21(DE3). This plasmid contains
the rck gene PCR amplified from the virulence plasmid of
Salmonella enterica serovar Typhimurium strain SL1344 and was
cloned into plasmid pBR322. Bacteria containing pRck or
pBR322 were cultured in the presence of ampicillin (100 mg/
ml). pRck was a kind gift from Dr. Nobuhiko Okada (Kitasato
University, Tokyo, Japan) and has been described previously [8].
Sera, proteins and antibodies
Normal human serum (NHS) was pooled from blood collected
from 7 to 10 healthy adult laboratory personnel with written
informed consent. The study protocol has been approved by the
Section for Research of the Helsinki University Central Hospital
Laboratory (project TYH7214). The blood was then allowed to
clot and the serum was subsequently harvested, pooled, aliquoted
and stored at 270uC until used. Heat-inactivated serum (HIS) was
generated by incubating NHS for 1 h at 56uC. Purified human
C4b and factor I were purchased from Calbiochem (San Diego,
CA). Human C4BP was purified according to the protocol of
Persson [21]. Bovine serum albumin and heparin were purchased
from Sigma-Aldrich. Single CCP deletion mutants of human
C4BP were purified as described [22]. Polyclonal rabbit anti-
human C3c (which recognizes the C3c portion of C3b, iC3b and
native C3) and monoclonal mouse anti-human C5b-9 (Dako,
Glostrup, Denmark), monoclonal mouse anti-human C4BP
MK104 [22], monoclonal mouse anti-human C4BP (Quidel,
San Diego, CA), and sheep polyclonal anti-human C4BP (The
Binding Site, Birmingham, UK) were used as primary antibodies
in flow cytometry experiments. The appropriate Alexa Fluor
labeled secondary antibodies were acquired from Invitrogen.
Direct C4BP binding assays
Bacteria were grown to stationary phase in 5 ml broth cultures
O/N using disposable 166125 mm tubes (BD Biosciences, San
Jose, CA). Thereafter, they were washed and resuspended in
Veronal buffered saline (142 mM NaCl, 1.8 mM sodium barbital,
3.3 mM barbituric acid, pH 7.4–7.6) supplemented with 0.1%
gelatin (GVB) to a final concentration of 16109 CFUs/ml. 20 ml of
this solution was then incubated with 20 ml of 125I-C4BP (,
20,000 cpm/sample) for 30 min at 37uC with agitation. After
incubation, the samples were centrifuged through 250 ml of 20%
sucrose/GVB at 10,000 x g to separate free protein from protein
bound to the bacteria. The supernatants and pellets were
separated and radioactivities were measured in a gamma counter.
The ratio of bound to total radioactivity was then determined.
Competition assays were performed by determining the relative
binding of 125I-C4BP in the presence of increasing amounts of
unlabeled C4BP, heparin, BSA, or NaCl.
Flow Cytometry
Bacteria grown as described above were centrifuged at 10,000 x
g for 3 min and resuspended in Dulbecco’s phosphate buffered
saline (DPBS) to a final OD600 of 0.4 (4610
8 CFU/ml). 25 ml of
the bacterial suspension was added to HIS or NHS (final
concentration specified for each experiment) or mixed with
purified human C4BP in DPBS (final concentration specified in
each experiment) to a final volume of 50 ml. Samples were
incubated at 37uC for the indicated times. The samples were
removed, centrifuged, and washed three times in 50 ml DPBS
supplemented with 1% BSA. After the final wash, bacteria were
resuspended in 50 ml DPBS/1% BSA. 20 ml of a 1:100 dilution of
the appropriate primary antibody (diluted in DPBS) was added to
the bacteria (final volume 70 ml) and incubated at room
temperature for 20 min. After washing in DPBS, bacteria were
resuspended in 50 ml DPBS, to which 20 ml of 1:200 dilution of the
appropriate Alexa Fluor 488-conjugated secondary antibody was
added, followed by incubation at room temperature in the dark for
20 min. The cells were washed twice as above and resuspended in
0.5 ml filtered DPBS containing 1% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA). Flow cytometric analysis was
performed on a FACscan (BD Biosciences) or Cyan ADP
cytometer (Beckman Coulter, Miami, FL).
Cofactor activity for C4b cleavage
Bacteria grown as described above were resuspended to a final
concentration of 16109 CFU/ml in DPBS. The bacteria were
then incubated with purified human C4BP at a final concentration
of 5 mg/ml. Following a 30 min incubation at 37uC, the bacteria
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were washed five times in DPBS. After the last wash, bacteria were
resuspended in DPBS and incubated with approximately 100,000
cpm of 125I-C4b and fI (15 mg/ml). After a 1 h incubation at 37uC,
the samples were centrifuged and the supernatants analyzed by
SDS-PAGE under reducing conditions. The gels were subse-
quently dried and the results visualized by autoradiography.
Statistical Analysis
Where appropriate, standard deviation (SD) and/or Student’s t-
test was performed for data comparison and assessment of
statistical significance.
Results
Rck binds to C4b-binding protein
In a previous study we observed that Rck expressed in E. coli
BL21 (DE3) binds the fluid-phase inhibitor of the alternative
pathway, fH [20]. The Rck homologue in Yersinia enterocolitica, Ail,
has been shown to bind C4BP [19]. We thus decided to test the
possibility that Rck also possesses this ability. As shown in
Figure 1A, we observed by FACS analysis that Rck expressed in E.
coli BL21 (DE3) can bind C4BP from HIS. This binding was not
was observed on the empty strain (Figure 1A) or on E. coli BL21
(DE3) expressing the empty vector, pBR322 (data not shown).
These results were corroborated in a direct binding assay using
radiolabeled C4BP (Figure 1B). Binding of C4BP to Rck was dose-
dependent and saturable, as addition of increasing amounts of
C4BP resulted in increased binding to Rck, reaching a plateau at
approximately 10 mg/ml (Figure 1C). No binding was observed in
the absence of Rck, even at the highest concentration of C4BP
used. Taken together, these results indicate that Rck binds C4BP.
C4BP bound to Rck exhibits functional activity
A cofactor assay was employed to determine if C4BP bound to
Rck is functional. In this assay, Rck-expressing bacteria are
incubated with purified C4BP and washed, followed by addition of
C4b and fI. As shown in Figure 2, incubation of purified C4BP
with C4b and fI results in the generation of the C4d and C4c
cleavage products. These cleavage products were also observed
when Rck-expressing bacteria were incubated with C4BP, washed,
and then incubated with C4b and fI. No cleavage was observed in
the absence of fI, suggesting that the bacteria do not possess
intrinsic cofactor activity. No cleavage was observed under any
conditions in the absence of Rck expression. Collectively, these
results suggest that C4BP bound to Rck is functional for fI-
mediated cleavage of C4b.
Reduced C3b and MAC deposition in the presence of Rck
Previous investigations have demonstrated that Rck expression
in Salmonella or E. coli confers resistance to both NHS and AP-only
serum [7,20]. As C4BP is an inhibitor of the classical pathway, we
wanted to test the possibility that Rck is able to inhibit C3b and
MAC deposition on the bacterial surface in the presence of all C
pathways. We first tested binding of IgG and IgM to the bacterial
surface, which is required for initiation of the CP. By FACS
analysis, we observed measurable IgG and IgM binding from HIS
on the bacterial surface regardless of the presence or absence of
Rck (Figure 3). We then tested the ability of Rck to inhibit C3b
and MAC deposition. Following a 10 minute incubation in 10%
NHS, we observed reduced C3b and MAC deposition on bacteria
expressing Rck compared to the empty strain (Figure 3). As we
observed higher levels of background on the Rck expressing strain
while measuring C3b and MAC (perhaps due to primary antibody
cross-reactivity with Rck), the data is also expressed as fold over
background (FOB), which is obtained by dividing the MFI value
from 10% NHS with the corresponding value from 10% HIS.
Taken together, these results suggest that the CP is active on the
strains employed and that Rck is capable of inhibiting C3b and
MAC in the presence of all C pathways.
C4BP binding competition assays
To determine the specificity of the interaction between C4BP
and Rck, we used either unlabeled C4BP or BSA as competitors to
the binding of radiolabeled C4BP. As shown in Figure 4, we
observed a dose-dependent reduction of radiolabeled C4BP
binding in the presence of increasing concentrations of unlabeled
C4BP, while increasing concentrations of BSA had no effect.
These results suggest that the interaction between Rck and C4BP
is specific. We further characterized the Rck-C4BP interaction by
testing the effects of heparin and NaCl. Increasing concentrations
of heparin or NaCl had no effect on binding of radiolabeled C4BP
to Rck, suggesting that C4BP binds to Rck via CCPs outside of the
heparin binding site (CCPs 1-3) and that the binding is mediated
by non-ionic interactions.
Mapping of the Rck binding site on C4BP
To identify the Rck binding site(s) on C4BP, we incubated
bacteria expressing Rck with purified human C4BP or with equal
amounts of recombinant C4BP mutants, each deficient in an
individual CCP. Amounts of bound protein were determined with
a polyclonal anti-human C4BP antibody followed by FACS
analysis. The MFI value obtained from wt C4BP bound to Rck
was set to 100% and the relative binding of the C4BP mutants
determined. As shown in Figure 5A, we observed a reduction in
binding of Rck to C4BP deficient in CCPs 7 and 8 (approximately
70% and 60% reduction, respectively). Due to the possibility that
the polyclonal anti-C4BP antibody employed in this experiment
may preferentially detect the C-terminal CCPs (such as CCPs 6-8),
we also measured binding of wt C4BP and the CCP7 and 8
mutants with monoclonal anti-C4BP antibody 104 (MK104),
which is specific for CCP1 of the a-chain. Consistent with the
results obtained with the polyclonal antibody, using MK104 we
observed an approximate 84% and 78% reduction in binding to
C4BP deficient in CCPs 7 and 8, respectively (Figure 4B). Taken
together, these results suggest that C4BP CCPs 7 and 8 may be
responsible for the interaction with Rck. As the heparin binding
sites on C4BP are located on CCPs 1-3 [23], the inability of
heparin to compete with the C4BP-Rck interaction (Figure 4) is
consistent with these results.
Discussion
In this work we demonstrate that the Salmonella outer membrane
protein Rck, when expressed in a normally serum-sensitive E. coli
host, can bind C4BP in a functional manner. This work extends
our previous observations that Rck can functionally recruit the key
fluid-phase inhibitor of the AP, fH [20]. C4BP binding is specific
and appears to involve CCPs 7 and 8 of C4BP. Collectively, these
results suggest that fH and C4BP recruitment play an important
role in Rck-mediated serum resistance.
The ability to inhibit multiple points in the complement
pathway likely increases the chances of a pathogen to escape
complement attack. This is demonstrated by the growing list of
bacterial pathogens which possess the ability to bind multiple
complement inhibitors [24]. In light of the results presented here,
Rck joins a growing list of proteins with the ability to bind both
C4BP and fH. Based on sequence comparisons of homologous
proteins Ail, Rck and PagC, which indicate high sequence
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similarity only in the membrane-spanning domains, it was initially
proposed that these proteins may be structurally similar but
functionally distinct [25]. The observation that Ail and Rck both
bind fH and C4BP (although with different sensitivities to salt and
heparin and different binding regions in fH) suggests the possibility
that these proteins may possess a structure particularly suited to
recruitment of these complement inhibitors.
Using a panel of C4BP mutants deficient in single CCPs of the
a-chain, we observed a reduction in Rck binding with C4BP
mutants lacking either CCP 7 or 8 (Figure 5). This result suggests
that CCPs 7 and 8 are important for the interaction with Rck, and
that there may be synergy between the two neighboring domains.
As the heparin binding sites in C4BP are found in CCPs 1-3, this
result was consistent with our observation that increasing heparin
concentrations had no effect on the C4BP-Rck interaction. A
survey of other bacterial pathogens which recruit C4BP reveals
that the N-terminal CCPs (CCPs 1-3) are important for interaction
with the M proteins of S. pyogenes [26,27] and the porin proteins
from N. meningitidis [28] and N. gonorrhoeae [13]. Both the N-
terminal and the C-terminal regions are involved in the interaction
with OmpA of E. coli K1 (CCPs 3 and 8) [14] and with an
unknown ligand of H. influenzae (CCPs 2 and 7) [17]. Collectively,
these results suggest that the N and C terminal, but not central
CCPs, are preferred for bacterial recruitment and exploitation. In
Figure 1. Rck is a C4BP binding protein. A, FACS analysis of C4BP binding. 26108 CFU/ml of BL21(DE3) and BL21(DE3) pRck in DPBS were mock
treated (DPBS only) or incubated with 10% HIS for 30 min. C4BP binding was measured by FACS using a mouse monoclonal anti-human C4BP
antibody. Mean fluorescence intensity (MFI) values are indicated. Representative data of an experiment performed at least three times are shown. B,
Direct binding of 125I-labeled C4BP to Rck. 16109 CFU/ml of BL21(DE3) and BL21(DE3) pRck in GVB were incubated with 125I-C4BP (, 20,000 cpm/
sample). The ratio of bound to total radioactivity was then determined (% bound). Data is expressed as means of two independent experiments
performed in duplicate 6 SD. C, Dose-dependent and saturable binding of C4BP to Rck. Bacteria prepared as in Figure 1A were incubated with
increasing amounts of purified C4BP and detected by FACS as described above using a polyclonal anti-C4BP antiserum. Data is expressed as means of
the MFI values acquired from three independent experiments 6 SD.
doi:10.1371/journal.pone.0027546.g001
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this regard, Rck is similar to other bacterial ligands for C4BP,
although there is currently no evidence to suggest structural
similarities between Rck and the ligands mentioned above.
In our C4BP binding assays we observed that incubation of
Rck-expressing bacteria with 1mg/ml purified human C4BP
resulted in greater C4BP binding compared to 10%NHS, which
contains approximately 20mg/ml C4BP (Figure 1A). This result
may be due to differences in affinity of the antibodies used; binding
of purified C4BP was determined using a polyclonal antiserum
while a monoclonal antibody was employed for detection from
HIS. Accordingly, the polyclonal antiserum may be capable of
simultaneously detecting multiple C4BP epitopes, thus leading to
increased fluorescence. Alternatively, although more C4BP is
present at this concentration of NHS, it is possible that C4BP may
be interacting with other serum components, thereby reducing its
availability to bind Rck. Conversely, it may also be possible that
other serum components are interacting with Rck and blocking
C4BP binding, although the observed serum resistance suggests
that the amount of bound C4BP is sufficient for protection against
complement attack.
Cirillo and colleagues have previously demonstrated that a point
mutation in the N-terminal region of the third surface exposed
loop of Rck, G118D, resulted in an approximate 1.6 log reduction
in serum survival when expressed in E. coli [29]. We tested the
possibility that this mutant would possess reduced C4BP binding
ability. By FACS analysis using purified C4BP, we observed that
the G118D mutation bound approximately 24-fold less C4BP
compared to wt Rck, although C4BP binding was not entirely
Figure 2. C4BP bound to Rck is functional for fI-mediated C4b
cleavage. Bacteria grown as in Figure 1B were incubated with purified
C4BP (5 mg/ml) for 30 min at 37uC and washed, after which fI (15 mg/ml)
and 125I-C4b (100,000 cpm) were added. After a 1h incubation at 37uC,
samples were analyzed with reducing SDS-PAGE and visualized by
autoradiography. The a’, b and c chains of C4b and the C4b cleavage
products are indicated by arrows and arrowheads, respectively.
Densitometry values are shown beneath each cleavage product. The
band intensities for the C4b only control were set to 100 and used as a
reference for the corresponding band obtained from the cofactor assay
performed in the presence of Rck. Representative data of an experiment
performed three times is shown.
doi:10.1371/journal.pone.0027546.g002
Figure 3. Deposition of IgG, IgM, C3b and MAC. Bacteria prepared as in Figure 1A were mock treated with DPBS (no serum) or incubated with
10% HIS or 10% NHS for 10 min at 37uC. IgG and IgM binding was measured by FACS analysis using goat anti-human IgG antibodies and rabbit anti-
human IgM, respectively. Bound C3b was detected using a polyclonal rabbit anti-human C3c antibody, which recognizes the C3b, iC3b and native C3
forms. MAC deposition was detected by a mouse-monclonal antibody specific for the C5b-9 complex. MFI and FOB (fold over background, the value
obtained when the MFI value from 10% NHS is divided by the corresponding value from 10% HIS) values are indicated. Representative data of an
experiment performed three times is shown.
doi:10.1371/journal.pone.0027546.g003
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Figure 4. Competition experiments. Characterization of C4BP binding to Rck. Direct binding of C4BP as performed in Figure 1B in the presence of
increasing concentrations of unlabeled C4BP, bovine serum albumin (BSA), heparin, or NaCl. Relative binding indicates the amount of C4BP bound in
the absence of competitor (set to 100%) compared to the amount bound in the presence of competitor. Data are shown as means of at least four
independent experiments 6SD.
doi:10.1371/journal.pone.0027546.g004
Figure 5. Localization of the Rck binding site on C4BP. A. BL21(DE3) pRck grown as in Figure 1A were mock treated (DPBS only) or incubated
with purified C4BP or recombinant C4BP deletion mutants (10 mg/ml), each with a single individual CCP deletion (D1-8). Bound C4BP (wt or mutant)
was detected with sheep polyclonal anti-human C4BP antibodies. The MFI value obtained from wt C4BP was set to 100% and used as a reference in
comparison to the MFI values obtained for all other samples. Data are shown as means of three independent experiments 6SD. *, p,0.01, compared
to wt C4BP. B. Detection of bound C4BP and CCP deletions 7 and 8 with MK104. Same experiment as A using MK104, which is specific for CCP1 of
C4BP. *, p,0.01, compared to wt C4BP.
doi:10.1371/journal.pone.0027546.g005
Salmonella Rck Binds C4BP
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27546
eliminated (data not shown). These results suggest that C4BP
binding plays an important role in the ability of Rck to mediate
serum resistance.
E. coli was chosen for these studies because it allows the serum
resistance phenotype to be studied in the absence of other serum
resistance factors in Salmonella which have been described.
Accordingly, the results presented here can be attributed to the
presence of Rck, as the background strain or the background
strain expressing the empty vector cannot mediate the serum
resistance phenotype. Nevertheless, the interpretation of these
results is restricted to this system. It is also important to note that
functional fH and C4BP binding was observed on Ail in Y.
enterocolitica O:3 provided that O-antigen or outer core hexasac-
charide were absent from LPS [18,19]. The E. coli BL21(DE3)
strain used in these studies has a truncated LPS with only the inner
core present, due to a defective galE gene. Although the ability of
Rck to mediate invasion of cultured eukaryotic cells and inhibit
MAC has been demonstrated in both Salmonella and E. coli
regardless of LPS length, [7,25,30], the ability to bind both fH and
C4BP in an appropriate Salmonella background and under
conditions of varying LPS length remains to be tested.
We have demonstrated that Rck is a functional C4BP binding
protein when expressed in a normally serum-sensitive heterologous
E. coli host. This work extends our previous observations
demonstrating functional fH binding ability in Rck. By recruiting
both C4BP and fH, Rck has the ability to inhibit all pathways of
complement at the convertase step, thus preventing complement-
mediated opsonization, lysis, and inflammation. These results
suggest that binding of complement inhibitors is critical for Rck-
mediated serum resistance.
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